A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma (NCT07533942)
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
🩺 Plain-English Summary (8th-Grade Level)
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
Who can join: Review the eligibility criteria below.
Location: Sutter Health — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Sutter Health — San Francisco, California
- Louisiana State University — New Orleans, Louisiana
- Mass General — Boston, Massachusetts
- NYU- Langone Health — New York, New York
- University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (215) 832-3750
Email: ClinicalTrialDisclosure@jazzpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Meningioma
- Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas — Chicago, Illinois
- A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas — Boston, Massachusetts
- Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma — New York, New York
- DOTATATE PET for Meningioma Radiation Planning — Vancouver, British Columbia
- Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC — New York, New York
Explore by condition: All Meningioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.